On March 5, 2020 Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, reported it will report its fourth quarter 2019 financial and operating results following the close of U.S. financial markets on Wednesday, March 11, 2020 (Press release, Novavax, MAR 5, 2020, http://ir.novavax.com/news-releases/news-release-details/novavax-host-conference-call-discuss-fourth-quarter-financial [SID1234555277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference call details are as follows:

Date: March 11, 2020
Time: 4:30 p.m.U.S. Eastern Time (ET)
Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode: 5695528
Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, March 11, 2020 until
7:30 p.m. ETMarch 18, 2020
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 5695528
Webcast: www.novavax.com, "Investors"/ "Events", until June 11, 2020